Daily scan of every earnings reaction moving 20% or more, either direction. Ranked within each column by mismatch -- overreactions and mixed calls first, clean justified moves last -- so the ones worth reading first are on top.
| Ticker | Move | Verdict | Sector |
|---|---|---|---|
| ★ DOCS | +85.5% | ⚠️ Overreaction | Healthcare |
| ★ PUBM | +36.6% | ⚠️ Overreaction | Technology |
| VATE | +50.0% | ◑ Mixed | Industrials |
| TEAM | +31.9% | ◑ Mixed | Technology |
| QNST | +30.2% | ◑ Mixed | Communication Services |
| FIGS | +26.8% | ◑ Mixed | Consumer Cyclical |
| RCEL | +23.7% | ◑ Mixed | Healthcare |
| FNKO | +20.3% | ◑ Mixed | Consumer Cyclical |
| FRD | +29.2% | ✅ Justified | Basic Materials |
| Ticker | Move | Verdict | Sector |
|---|---|---|---|
| ★ CVRX | -43.1% | ⚠️ Overreaction | Healthcare |
| ★ TTD | -29.3% | ⚠️ Overreaction | Technology |
| HCAT | -26.7% | ⚠️ Overreaction | Healthcare |
| SEZL | -26.5% | ⚠️ Overreaction | Financial Services |
| BAER | -20.7% | ⚠️ Overreaction | Industrials |
| SRTS | -26.6% | — Unclear | Healthcare |
| XPOF | -26.7% | ✅ Justified | Consumer Cyclical |
| ORGO | -22.0% | ✅ Justified | Healthcare |
DOCS — Doximity, Inc. (+85.5%)
Doximity reported Q1 FY2027 results with revenue of $156.6M (up 7% YoY), beating consensus by 3.2% ($156.6M vs. $151.8M estimate), but EPS came in at $0.29 versus $0.30 expected—a 4.3% miss on the bottom line. The real concern was operational deterioration: adjusted EBITDA fell 6% YoY to $74.8M despite revenue growth, margins compressed from 54.7% to 47.7%, and free cash flow dropped 34% YoY to $39.6M. Management guided Q2 revenue to $170–171M (midpoint ~$170.5M, implying only 6% growth) and full-year revenue to $671–681M, suggesting decelerating momentum ahead. While the company highlighted AI adoption (Ask benchmark win, 25% QoQ growth in AI Search), record engagement, and 30%+ prescriber workflow growth, these operational metrics don't justify an 85% single-day rally on a revenue beat that barely exceeded estimates and an EPS miss paired with margin compression and cash flow deterioration.
View DOCS →PUBM — PubMatic, Inc. (+36.6%)
PubMatic reported a strong earnings beat with EPS of -$0.03 versus an estimate of -$0.18 (an 83.3% surprise), and revenue of $78.6 million against a $69.0 million estimate, representing a 14% revenue beat and a return to double-digit year-over-year growth ahead of schedule. The company also announced expanded profitability and has maintained 41 consecutive quarters of adjusted EBITDA profitability since 2016. However, the same day brought news of CFO Steve Pantelick's planned retirement after 15 years, with a transition period extending through mid-2027—a significant operational uncertainty that typically warrants caution. While the operational metrics are genuinely strong, a 36.6% single-day rally on an EPS beat from deeply negative territory (-$0.03 is still unprofitable on a GAAP basis) and a mid-teen revenue beat appears disproportionate when weighted against the leadership transition risk and the fact that profitability is only achieved on an adjusted basis, not reported earnings. The magnitude of the move suggests the market is pricing in a re-rating of the entire business rather than responding proportionally to the sequential improvement in execution.
View PUBM →VATE — INNOVATE Corp. (+50.0%)
INNOVATE Corp. (VATE) surged 50% on a massive EPS beat—posting $0.71 diluted EPS versus a -$2.18 estimate, a +132.5% surprise—and revenue of $421.6M versus $251.7M guidance (a +67.5% beat). The driver was Infrastructure's DBMG segment, which posted 77.6% YoY revenue growth to $414M with record $2.7B adjusted backlog, 350bps EBITDA margin expansion, and $48.7M Adjusted EBITDA. However, critical context tempers the celebration: the EPS beat was heavily aided by a one-time $18.7M gain on debt extinguishment from Broadcasting's refinancing, and management is actively selling both DBMG (the earnings engine) and a 75% stake in Broadcasting. The company remains in restructuring mode with only $1.5M corporate cash and mounting debt refinancing costs; H1 2026 earnings are still -$6.8M despite strong Q2. A 50% rally on what is partly a refinancing accounting benefit and an asset sale pipeline—not sustained operating leverage—appears stretched, especially given the company is dismantling the very business (DBMG) driving the beat.
View VATE →TEAM — Atlassian Corporation (+31.9%)
Atlassian delivered a strong Q4 FY2026 with non-GAAP EPS of $1.87 beating estimates by 24.7% ($1.50) and revenue of $1.77B beating by 6.2% ($1.66B estimate), supported by 28% YoY revenue growth, 31% cloud revenue acceleration, and 23% ARR growth to $6.6B. The company also achieved GAAP profitability (12% operating margin vs. -2% prior year) and delivered robust forward guidance with FY2027 total revenue growth of 13% and cloud growth of 25.5%, alongside a crucial 44% YoY RPO increase to $4.8B signaling strong future revenue visibility. However, the 31.9% stock rally appears somewhat outsized relative to the core print: the 24.7% EPS beat is meaningful but comes on a modest 6.2% revenue beat, and while the ARR and RPO metrics are solid, FY2027 total revenue growth guidance of 13% represents a significant deceleration from the 28% Q4 performance, suggesting the market is pricing in either a substantial multiple expansion or confidence in upside execution beyond the provided targets. The AI narrative around the Teamwork Graph and 1M MAU milestone on MCP server tools provides strategic color, but without specific revenue attribution or margin accretion from these initiatives, it remains speculative fuel rather than a concrete earnings driver justifying a near-one-third revaluation.
View TEAM →QNST — QuinStreet, Inc. (+30.2%)
QuinStreet delivered a modest EPS beat of +13.2% ($0.50 vs. $0.4417 estimate) and a revenue beat of +3.9% ($373.9M vs. $359.9M estimate), capping a record fiscal year with 43% Q4 revenue growth and 87% Adj. EBITDA growth year-over-year. However, the forward guidance is the real story: FY2027 revenue guidance of $1.45–$1.55B implies only 16% midpoint growth versus the 43% Q4 growth just posted, and Adj. EBITDA growth is guided to 38% (midpoint) versus 87% in the quarter—a dramatic deceleration despite management's bullish rhetoric on market opportunity and margin expansion. A 30.2% stock rally on a 13% earnings surprise and decelerating forward growth suggests the market is pricing in either a significant multiple re-rating on improved profitability visibility or assuming management's FY2027 guidance is conservatively anchored and will be raised materially, neither of which the earnings call itself supports with concrete catalysts. The margin expansion narrative (160 basis points guided for FY2027) is real but incremental, and without evidence of major new contracts or market share wins beyond "relentless digital shift" commentary, the 30% move appears disproportionate to the fundamentals on display.
View QNST →FIGS — FIGS, Inc. (+26.8%)
FIGS crushed expectations on both top and bottom lines: EPS beat by 123% ($0.15 actual vs. $0.067 estimate) and revenue exceeded by 5.6% ($196.6M vs. $186.2M), while posting a remarkable 28.8% year-over-year revenue growth and expanding net income margin to 14.4% from 4.7%. The company also raised full-year guidance (net revenue growth ~20%, adjusted EBITDA margin 14.8–15.0%) and authorized an additional $100M share repurchase, signaling confidence in momentum. However, a 26.8% stock rally on a 123% EPS beat with 5.6% revenue beat warrants scrutiny: while the profitability inflection is genuine—driven partly by 78 basis points of IEEPA tariff refunds and operating leverage—the magnitude of the stock move prices in substantial re-rating premium beyond the quarter's fundamentals. The business is demonstrably accelerating (three consecutive quarters of 25%+ growth, improving unit economics, international growing 67%), but a ~27% pop appears to reflect investor relief or re-rating rather than a proportionate response to the earnings upside alone.
View FIGS →RCEL — AVITA Medical, Inc. (+23.7%)
AVITA Medical's 23.7% rally on Q2 earnings was driven by a modest 14.6% EPS beat (−$0.25 vs. −$0.29 est.), 7.2% revenue beat ($21.7M vs. $20.3M est.), and record sequential growth of 18% YoY and 13% QoQ, paired with gross margin expansion to 81.9% and operating expense discipline (down 6% YoY). The company raised full-year revenue guidance to $86–$89M (from $80–$85M), a midpoint increase of 6.3%, and announced an expected path to Q4 2026 cash flow breakeven—a material inflection point. However, the stock's move significantly outpaces the operational data alone: the EPS beat represents a marginal improvement in loss magnitude, and the revenue beat of 7.2% does not typically warrant a 24% move, even with guidance raised. The cash position remains tight at $11.1M (down from $14.3M at quarter start), and the business still burns cash at a meaningful rate ($3.2M in Q2). The CMS reimbursement announcement for RECELL in 2027, while favorable for long-term physician adoption and pricing transparency, is more forward-looking and less concrete than immediate margin expansion. The rally appears partially justified by the guidance raise and cash breakeven milestone, but priced in significant re-rating and execution risk beyond what the Q2 beat alone supports.
View RCEL →FNKO — Funko, Inc. (+20.3%)
Funko delivered a solid but not extraordinary earnings beat: EPS came in at $0.26 versus a loss estimate of −$0.21 (a +226% surprise), while revenue hit $207.7M versus $201.0M guidance (+3.3% beat). The headline driver was a $25.4M tariff refund benefit that inflated both Q2 profitability and full-year Adjusted EBITDA guidance (raised to $100M–$110M from $70M–$80M). Stripping out this one-time benefit, the operational story is modest: 7% net sales growth, a record 56.6% gross margin (56.1% ex-tariff), and $15M of net income—improvements driven partly by SG&A discipline (down 413 bps as a percentage of sales), but guidance for Q3 calls for flat sales growth and Adjusted EBITDA of only $25M–$30M, well below Q2's $40.9M. A +20% stock rally on a 3% revenue beat and a one-time tariff windfall that management itself excluded from forward guidance suggests the market is pricing in a permanent margin expansion or a business re-rating that the underlying Q2 operational results and muted Q3 outlook do not fully support.
View FNKO →FRD — Friedman Industries, Incorporated (+29.2%)
Friedman Industries reported a blockbuster first quarter for fiscal 2027 ended June 30, 2026, with net earnings of $12.8 million ($1.79 diluted EPS) on sales of $240.0 million, representing a 155% increase in net earnings and 78% revenue growth year-over-year from $5.0 million ($0.71 EPS) on $134.8 million in sales. The company achieved record quarterly sales volume of 206,000 tons (up 28% YoY), with organic growth at legacy facilities accounting for 33,000 tons of the increase, while EBITDA surged 135% to $19.3 million from $8.2 million. Management guided for second quarter volumes to remain "comparable to first quarter" with anticipated sequential margin expansion from higher average selling prices—a highly constructive near-term outlook for a cyclical industrial company. The 29.2% stock rally appears justified by the magnitude of earnings acceleration (155% EPS growth), broad operational improvements (volume, pricing, and margin expansion), the successful integration of the Century Metals acquisition, and forward visibility into sustained strength, though some caution is warranted given the cyclical nature of metals processing and the company's dependency on raw material and steel price dynamics.
View FRD →CVRX — CVRx, Inc. (-43.1%)
CVRx reported a modest -1.0% EPS miss (-$0.53 vs. -$0.5246 estimate) alongside a revenue beat of 1.0% ($15.7M vs. $15.5M estimate), with solid operational fundamentals including 16% YoY revenue growth, 87% gross margin (up 300 bps), 258 active implanting centers (up 18 YoY), and a major reimbursement win from Humana's Medicare Advantage coverage policy. However, management guided full-year revenue to $58–60M (implying ~3.3–4.3% sequential growth in H2 versus H1's strong pace) and cited specific near-term headwinds: fewer-than-expected sales territories, lower sales force productivity, and payer challenges. The 43% stock drop appears disproportionate to a near-zero earnings surprise and a reaffirmed but cautious outlook; the miss is essentially rounding error, and the revenue beat plus strong margin expansion and coverage wins suggest the business model remains intact despite near-term execution friction that management characterized as addressable. A repricing of growth expectations warranted a pullback, but a 43% crash suggests the market either panicked over guidance conservatism or priced in a much larger operational deterioration than the actual numbers support.
View CVRX →TTD — The Trade Desk, Inc. (-29.3%)
The Trade Desk delivered a massive non-GAAP EPS beat of +89.9% ($0.34 vs. $0.179 estimate), but revenue missed estimates by 5% ($715M vs. $753M), growing only 3% year-over-year in Q2—a significant deceleration from 19% growth in the prior year. Management openly stated "this quarter did not meet the standard we set for ourselves," and forward guidance reflects continued softness: Q3 revenue guidance of at least $650M (implying 1–4% growth) and Adjusted EBITDA of ~$160M. The EPS beat was entirely a non-GAAP construct powered by stock-based compensation adjustments and share buybacks ($78M repurchased in Q2), while GAAP EPS actually declined to $0.14 from $0.18 year-over-year. The 29% stock collapse reflects genuine business deceleration (revenue growth halved, Adjusted EBITDA margins compressed from 39% to 34%), but the magnitude suggests the market had previously priced in stabilization, not continued deterioration—a repricing rather than a proportionate response to operational misses alone.
View TTD →HCAT — Health Catalyst, Inc. (-26.7%)
Health Catalyst reported a 33.8% EPS beat ($0.04 actual vs. $0.03 estimate) and exceeded revenue guidance with $70.5M in Q2 sales, plus management highlighted debt repayment and the Vitalware divestiture closing as major balance-sheet wins. However, the headline numbers mask significant operational deterioration: total revenue declined 13% YoY to $70.5M, adjusted EBITDA grew only 6% YoY to $9.9M despite cost cuts, and critically, Q3 guidance collapsed to $55–56M revenue (implying a 22% sequential drop) with adjusted EBITDA guidance of $0–$0.5M—a 95% decline from Q2's $9.9M run rate. The guidance crater, not the Q2 beat, is the real story, yet a -26.7% drop punishes the stock beyond what the Q3 cliff warrants when the underlying business is cutting costs and deleveraging; the move appears to price in a growth crisis rather than a temporary seasonal dip, which is disproportionate to one quarter of weak forward guidance.
View HCAT →SEZL — Sezzle Inc. (-26.5%)
Sezzle delivered a strong Q2 2026 earnings beat with EPS of $1.13 (adjusted) vs. the $1.03 consensus estimate (+9.7% surprise) and revenue of $149.7M vs. $135.1M expected (+10.8% beat), alongside exceptional operational metrics: 51.7% YoY revenue growth, 76.4% YoY subscriber growth to 854K (described as the largest YoY gain in company history), and 37.9% GMV growth to $1.3B. Management raised full-year 2026 guidance for the third time, raising adjusted net income to $185M from $180M and adjusted EPS to $5.25 from $5.10, reflecting confidence in momentum from new products (SezzleCash, Sezzle Send), a substantially improved $300M credit facility (290 bps lower spread), and record purchase frequency of 7.2x. The 26.5% stock decline appears severely disconnected from a beat of this magnitude paired with raised guidance and accelerating business momentum; even a conservative investor would struggle to justify a quarter-sized drop on a 10% revenue beat, triple-digit subscriber growth, and multiple guidance raises in a single fiscal year.
View SEZL →BAER — Bridger Aerospace Group Holdings, Inc. Common Stock (-20.7%)
Bridger Aerospace reported Q2 2026 revenue of $30.5M versus the $37.0M estimate (a 17.6% miss) and EPS of -$0.13 versus -$0.03 expected (a 333% miss on the loss side), triggering a 20.7% stock decline. However, the company reiterated full-year 2026 guidance of $135–$145M revenue (14% growth at midpoint) and $55–$60M Adjusted EBITDA (27% growth), while simultaneously announcing a $58M multi-year Texas A&M contract, extending Super Scooper task orders to 160 days (longest in company history), and entering European operations via a Portugal wildfire contract. Stripping non-recurring items, core Q2 revenue grew 16% year-over-year, and the company cited record-long government commitments extending into Q4 amid heightened 2026 wildfire activity (5M+ acres burned, up 2M year-over-year). The 21% drop appears disproportionate to a single quarterly shortfall when offset against reaffirmed full-year guidance, major contract wins, and forward deployment visibility—a classic overreaction to timing volatility in a seasonal aerospace services business.
View BAER →SRTS — Sensus Healthcare, Inc. (-26.6%)
Unable to assess the proportionality of Sensus Healthcare's (SRTS) 26.6% stock decline on 2026-08-06 earnings due to complete absence of reported financial data. The source documents provided contain no estimate/actual figures, earnings metrics, revenue comparisons, guidance changes, or any company-specific information related to SRTS—instead offering only unrelated articles about Apple, OpenAI, and broader tech sector commentary. Without concrete earnings numbers (EPS beat/miss percentages, revenue variance, guidance deltas, or operational catalysts), it is impossible to determine whether the sharp drop reflects genuine business deterioration or represents a market overreaction to undefined news. Any verdict on this move requires the actual earnings release details for SRTS, which are not available in these sources.
View SRTS →XPOF — Xponential Fitness, Inc. (-26.7%)
Xponential Fitness reported a catastrophic earnings miss with adjusted EPS of $0.02 versus $0.1259 consensus—an 84% shortfall—while revenue barely beat at $66.0M versus $64.4M (a meager 2.4% beat that pales in comparison). The company simultaneously slashed full-year guidance across the board: adjusted EBITDA down 16% at the midpoint ($91–$97M vs. prior $100–$110M), revenue down 19% ($250–$260M vs. $260–$270M), and net studio openings cut 25% to 150. The underlying business deteriorated sharply—North America same-store sales declined 6.8% versus prior-year growth of 2.4%, adjusted EBITDA fell 22% year-over-year to $21.9M, and the company burned $25.7M in operating cash in Q2 alone. While a 27% stock drop appears severe, the 84% EPS miss combined with slashed full-year earnings guidance of 16% and a fundamental business deceleration (declining same-store sales, falling unit volumes, and negative cash burn) justifies the magnitude of the selloff; this was not a minor execution miss but a reset of expectations across profitability and growth.
View XPOF →ORGO — Organogenesis Holdings Inc. (-22.0%)
Organogenesis reported a substantial earnings miss with EPS of -$0.71 versus the consensus estimate of -$0.35, representing a 103% negative surprise, while revenue came in at $43.8 million against expectations of $54.3 million—an 19.4% shortfall. The company provided no forward guidance or strategic commentary in the available materials, leaving investors in the dark about management's outlook and turnaround plans. A combined 103% EPS beat/miss coupled with a 19.4% revenue miss on a relatively small revenue base suggests material operational deterioration rather than a minor execution issue. While a 22% stock decline is severe, the magnitude of both earnings and revenue misses—particularly the complete guidance void—justifies meaningful downside repricing, as investors are now pricing in both near-term cash burn (negative earnings) and uncertainty about management's confidence in the business.
View ORGO →